Adjuvant therapy decisions may also concern the recommendation for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for patients with higher-risk HR+/Her2− BC [81,82,83]. This evidence concerns the gene CDK4 and breast cancer.